GB201706945D0 - Self-inactivating viral vector - Google Patents

Self-inactivating viral vector

Info

Publication number
GB201706945D0
GB201706945D0 GBGB1706945.1A GB201706945A GB201706945D0 GB 201706945 D0 GB201706945 D0 GB 201706945D0 GB 201706945 A GB201706945 A GB 201706945A GB 201706945 D0 GB201706945 D0 GB 201706945D0
Authority
GB
United Kingdom
Prior art keywords
self
viral vector
inactivating viral
inactivating
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1706945.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Kingdom Research and Innovation
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to GBGB1706945.1A priority Critical patent/GB201706945D0/en
Publication of GB201706945D0 publication Critical patent/GB201706945D0/en
Priority to PCT/GB2018/051166 priority patent/WO2018203049A1/en
Priority to CN201880029221.8A priority patent/CN110914439B/zh
Priority to EP18723917.3A priority patent/EP3619314B1/en
Priority to JP2019560380A priority patent/JP7420558B2/ja
Priority to AU2018262281A priority patent/AU2018262281B2/en
Priority to US16/607,980 priority patent/US12203092B2/en
Priority to KR1020197035530A priority patent/KR20200015900A/ko
Priority to BR112019023003A priority patent/BR112019023003A2/pt
Priority to CA3060675A priority patent/CA3060675A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/609—Vectors comprising as targeting moiety peptide derived from defined protein from viruses positive strand RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1706945.1A 2017-05-02 2017-05-02 Self-inactivating viral vector Ceased GB201706945D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB1706945.1A GB201706945D0 (en) 2017-05-02 2017-05-02 Self-inactivating viral vector
CA3060675A CA3060675A1 (en) 2017-05-02 2018-05-02 Self-inactivating viral vector
JP2019560380A JP7420558B2 (ja) 2017-05-02 2018-05-02 自己不活性化ウイルスベクター
CN201880029221.8A CN110914439B (zh) 2017-05-02 2018-05-02 自灭活病毒载体
EP18723917.3A EP3619314B1 (en) 2017-05-02 2018-05-02 Self-inactivating viral vector
PCT/GB2018/051166 WO2018203049A1 (en) 2017-05-02 2018-05-02 Self-inactivating viral vector
AU2018262281A AU2018262281B2 (en) 2017-05-02 2018-05-02 Self-inactivating viral vector
US16/607,980 US12203092B2 (en) 2017-05-02 2018-05-02 Self-inactivating rabies virus vector encoding a nucleoprotein and degron
KR1020197035530A KR20200015900A (ko) 2017-05-02 2018-05-02 자가-비활성화 바이러스 벡터
BR112019023003A BR112019023003A2 (pt) 2017-05-02 2018-05-02 vetor viral auto-inativante

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1706945.1A GB201706945D0 (en) 2017-05-02 2017-05-02 Self-inactivating viral vector

Publications (1)

Publication Number Publication Date
GB201706945D0 true GB201706945D0 (en) 2017-06-14

Family

ID=59011153

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1706945.1A Ceased GB201706945D0 (en) 2017-05-02 2017-05-02 Self-inactivating viral vector

Country Status (10)

Country Link
US (1) US12203092B2 (https=)
EP (1) EP3619314B1 (https=)
JP (1) JP7420558B2 (https=)
KR (1) KR20200015900A (https=)
CN (1) CN110914439B (https=)
AU (1) AU2018262281B2 (https=)
BR (1) BR112019023003A2 (https=)
CA (1) CA3060675A1 (https=)
GB (1) GB201706945D0 (https=)
WO (1) WO2018203049A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021004389A1 (zh) * 2019-07-05 2021-01-14 司龙龙 蛋白水解靶向病毒、其活疫苗及其制备方法和用途
CA3208612A1 (en) * 2021-02-19 2022-08-25 Beam Therapeutics Inc. Recombinant rabies viruses for gene therapy
AU2022264328A1 (en) * 2021-04-27 2023-11-16 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Recombinant cedar virus chimeras
CN115704012A (zh) * 2021-08-12 2023-02-17 中国科学院深圳先进技术研究院 一种含有降解决定子的重组病毒及其制备方法和应用
CA3230629A1 (en) * 2021-09-08 2023-03-16 Beam Therapeutics Inc. Viral guide rna delivery
CN116262911B (zh) * 2021-12-14 2026-02-17 中国科学院深圳先进技术研究院 一种减毒、复制可控的顺向hsv示踪系统及其构建方法和应用
CN114058641B (zh) * 2022-01-17 2022-04-01 苏州大学 一种载体系统和应用及通过其降解目的蛋白的方法
CN116676273A (zh) * 2022-02-22 2023-09-01 中国科学院深圳先进技术研究院 一种蛋白水解靶向流感病毒及其制备方法和应用
CN120366391A (zh) * 2023-04-18 2025-07-25 上海本导基因技术有限公司 一种用于治疗亨廷顿疾病的慢病毒样颗粒
CN117867029B (zh) * 2023-12-29 2024-12-20 复百澳(苏州)生物医药科技有限公司 一种狂犬亚型假病毒的制备方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0500722A2 (hu) * 2001-07-20 2005-11-28 The University of Georgia Research Foundation, Inc@Á Attenuált veszettség vírus, a veszettség elleni vakcináláshoz és a központi idegrendszer génterápiájához egy nukleoprotein mutációval a foszforilezés helyén
US7608682B2 (en) 2002-10-30 2009-10-27 Meso Scale Technologies Llc Substrates of N-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrates
US9212359B2 (en) 2011-06-23 2015-12-15 Sanford Jay Silverman Systems for induction of gene expression and protein depletion in yeast
US20180195085A1 (en) 2015-02-02 2018-07-12 Id Pharma Co., Ltd. Improved negative-strand rna viral vector
US10550379B2 (en) * 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production

Also Published As

Publication number Publication date
US12203092B2 (en) 2025-01-21
CN110914439A (zh) 2020-03-24
KR20200015900A (ko) 2020-02-13
CA3060675A1 (en) 2018-11-08
EP3619314A1 (en) 2020-03-11
WO2018203049A1 (en) 2018-11-08
EP3619314B1 (en) 2021-11-10
CN110914439B (zh) 2024-05-17
AU2018262281A1 (en) 2019-11-14
AU2018262281B2 (en) 2024-05-09
JP2020518265A (ja) 2020-06-25
JP7420558B2 (ja) 2024-01-23
US20210115472A1 (en) 2021-04-22
BR112019023003A2 (pt) 2020-05-19

Similar Documents

Publication Publication Date Title
IL277666A (en) Virus vector evasion antibody
IL277664A (en) Virus vector evasion antibody
GB2549809B (en) Vector
IL274178A (en) Add-with-carry vector instruction
SG11202001367QA (en) Retroviral vectors
GB201706945D0 (en) Self-inactivating viral vector
GB201614093D0 (en) Vector
GB201814590D0 (en) Viral vector production system
GB201509578D0 (en) Vectors
IL274278A (en) vectors
GB2590774B (en) Vector
EP3310369A4 (en) Self-limiting viral vectors encoding nucleases
PL3325631T3 (pl) Rekombinowany wektor wirusa orf
GB201717524D0 (en) Vectors
GB201705927D0 (en) Vector
GB201509881D0 (en) Complementary vectors
GB2566572B (en) Methods for adeno-associated viral vector production
ZA202108996B (en) Viral vector
GB201913974D0 (en) Vector
GB201718294D0 (en) Vector construct
GB201906283D0 (en) Vector
HK40022890A (en) Self-inactivating viral vector
GB201914984D0 (en) Vector
HK40027046A (en) Vector construct
HK40004437A (en) Viral vector stabilization

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: UNITED KINGDOM RESEARCH AND INNOVATION

Free format text: FORMER OWNER: MEDICAL RESEARCH COUNCIL

AT Applications terminated before publication under section 16(1)